# Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium

Canonical: https://abierto.us/opportunities/rrpv2613bundivx

- Solicitation number: RRPV-26-13-BundiVx
- Notice type: Solicitation
- Status: Closed. Deadline was July 2, 2026 at 1:00 PM EDT
- Department: Department of Health and Human Services
- Agency: Office of Assistant Secretary for Preparedness and Response
- Contracting office: Barda - Aspr / Daappo / Barda DCMA (75A501)
- NAICS: 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Product or service code: AN23 Health R&D Services; Health Research And Training; Experimental Development
- Place of performance: Washington, District of Columbia
- County: District of Columbia (FIPS 11001). https://abierto.us/counties/district-of-columbia-dc-11001
- City: Washington. https://abierto.us/cities/washington-dc-1150000
- First posted: June 11, 2026
- Last posted: June 18, 2026
- SAM.gov: https://sam.gov/workspace/contract/opp/39416da2c4234eb6be171677294465c5/view

## Description

**UPDATE:** Question and Answers attached in documents. Date for submission revised to July 2, 2026. The Office of Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) seeks to use the Rapid Response Partnership Vehicle (RRPV) Consortium, an enterprise partnership in collaboration with industry and academia to facilitate research and development activities as follows:

The purpose of this RPP is to advance investigational BDBV vaccine candidates leveraging the VSV vaccine platform, which has demonstrated single dose protection in past EBOV outbreaks. Work includes manufacturing process development through production of initial current Good Manufacturing Practice (cGMP) Phase 1 clinical trial material (CTM), with a goal of up to 10,000 doses. Early regulatory engagement will inform the critical-path IND-enabling nonclinical.

The proposed approach must describe how any available platform efficiencies from prior or ongoing platform development and manufacturing to accelerate the path towards cGMP CTM production and IND submission under the U.S. FDA. Additional activities include a Phase 1 safety and immunogenicity trial as well as options for production of up to 100,000 doses of cGMP CTM.

The end goal of this effort is (1) to produce cGMP CTM and meet regulatory requirements to enable use of investigational candidate(s) in a clinical trial for the ongoing 2026 BDBV outbreak and (2) to identify successful BDBV vaccine candidates for potential further development. Please see the attachments for more information. Questions are due June 16, 2026 by 12 p.m. Eastern. Proposals are due by June 26 at 3 p.m. Eastern. Submission link: https://www.rrpv.org/solicitation/bundibugyo-virus-outbreak-response-vaccines-bundivx/

## Publications

- June 11, 2026: Solicitation, due June 26, 2026 at 3:00 PM EDT. Notice c98854cab79546668cbdfcf9ab9e873b. https://sam.gov/workspace/contract/opp/c98854cab79546668cbdfcf9ab9e873b/view
- June 17, 2026: Solicitation, due July 2, 2026 at 1:00 PM EDT. Notice 3063f3ea250545ac9a61c44b0e662572. https://sam.gov/workspace/contract/opp/3063f3ea250545ac9a61c44b0e662572/view
- June 17, 2026: Solicitation, due July 2, 2026 at 1:00 PM EDT. Notice edf1fe7881b54021852866cdae5b512c. https://sam.gov/workspace/contract/opp/edf1fe7881b54021852866cdae5b512c/view
- June 18, 2026: Solicitation, due July 2, 2026 at 1:00 PM EDT. Notice 39416da2c4234eb6be171677294465c5. https://sam.gov/workspace/contract/opp/39416da2c4234eb6be171677294465c5/view

## Points of contact

- Veronica Stroud, veronica.stroud@hhs.gov, 2027313103
- Jonathan Gonzalez, Contracting Officer, Jonathan.Gonzalez@hhs.gov

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/rrpv2613bundivx.